Recently, dasatinib was shown to enhance the sensitivity of KRAS mutant cells to trametinib (MEK1/MEK2 inhibitor) in different cancer types, including H23 and H358 NSCLC cell lines. This evidence concerns the gene MAP2K1 and cancer.